Weekly Genomic Health, Inc. (NASDAQ:GHDX) Ratings on May 16, 2018

May 16, 2018 - By Mark Mitchell

Genomic Health, Inc. (NASDAQ:GHDX) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.13. That’s change of 1.19, from 2017Q3’s 2.32. 18 investors sold all, 35 reduced holdings as Genomic Health, Inc. ratio dived. 42 grew positions while 18 funds took positions. Funds hold 31.21 million shares thus 1.14% more from 2017Q3’s 30.86 million shares.
Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,263 shs or 0% of their US capital. State Farm Mutual Automobile Insur Company invested in 0.02% or 350,741 shs. Ameritas Prns reported 0% in Genomic Health, Inc. (NASDAQ:GHDX). The New Jersey-based Prudential Financial has invested 0.01% in Genomic Health, Inc. (NASDAQ:GHDX). First Bank Of Omaha owns 30,105 shs or 0.06% of their US capital. Alliancebernstein Ltd Partnership invested in 0% or 37,885 shs. Ny State Common Retirement Fund holds 0% or 22,900 shs in its capital. Voya Invest Mngmt Llc accumulated 8,622 shs. Proshare Advsr Ltd Limited Liability Company reported 21,674 shs or 0.01% of all its holdings. Us Financial Bank De reported 4,322 shs. Dubuque Savings Bank And Tru holds 5,069 shs. Royal State Bank Of Canada reported 0% of its capital in Genomic Health, Inc. (NASDAQ:GHDX). York Capital Mngmt Global Advisors Lc reported 12,370 shs. 71,626 were reported by Oppenheimer &. Camber Mgmt Limited Liability Com, a Massachusetts-based fund reported 2.46 million shs.

Genomic Health, Inc. had 16 insider sales and 0 buys since December 12, 2017. This’s net activity of $4.15 million. On Tuesday, February 20 Leber Laura sold $111,080 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 3,374 shs. Shares for $102,406 were sold by Vaughn James J. On Tuesday, March 13 Cole G Bradley also sold $164,014 worth of Genomic Health, Inc. (NASDAQ:GHDX). Shares for $197,298 were sold by Febbo Phillip G. on Tuesday, December 19. Another trade for 5,500 shs valued at $201,543 was made by Shak Steven on Wednesday, May 9.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

In total 8 analysts cover Genomic Health (NASDAQ:GHDX). “Buy” rating has 1, “Sell” are 3, while 4 are “Hold”. 13% are bullish. 9 are the (NASDAQ:GHDX)’s analyst reports since December 13, 2017 according to StockzIntelligence Inc. On Wednesday, December 13 JP Morgan downgraded the shares of GHDX in report to “Underweight” rating. On Wednesday, December 20 William Blair downgraded the shares of GHDX in report to “Hold” rating. On Tuesday, January 16 the firm has “Buy” rating by Canaccord Genuity given. On Thursday, March 8 the firm has “Hold” rating by Piper Jaffray given. On Friday, March 9 Canaccord Genuity maintained Genomic Health, Inc. (NASDAQ:GHDX) rating. Canaccord Genuity has “Buy” rating and $40.0 target. On Wednesday, December 13 the rating was downgraded by J.P. Morgan to “Sell”. In Thursday, May 3 report Deutsche Bank maintained the stock with “Hold” rating. Listed here are Genomic Health, Inc. (NASDAQ:GHDX) PTs and latest ratings.

03/05/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $32 New Target: $34 Maintain
09/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $40.0 Maintain
08/03/2018 Broker: Piper Jaffray Rating: Hold New Target: $33.0 Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $42.0 Maintain
04/01/2018 Broker: Barclays Capital Rating: Sell New Target: $28.0
20/12/2017 Broker: William Blair Rating: Hold Downgrade
14/12/2017 Broker: Raymond James Rating: Hold
13/12/2017 Broker: J.P. Morgan Rating: Sell New Target: $25.0 Downgrade
13/12/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

The stock decreased 0.50% or $0.19 during the last trading session, reaching $37.81.Genomic Health, Inc. has 189,710 shares volume, 2.39% up from normal. GHDX is downtrending and has moved 2.07% since May 16, 2017. GHDX underperformed the S&P 500 by 13.62%.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally.The company has $1.34 billion market cap. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.Last it reported negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

More recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by Prnewswire.com, Benzinga.com and Seekingalpha.com. The first one has “Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference” as a title and was published on May 09, 2018. The next is “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. And last was published on May 03, 2018, called “Genomic Health’s (GHDX) CEO Kimberly Popovits on Q1 2018 Results – Earnings Call Transcript”.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.